Research Analysts Set Expectations for EPRX FY2026 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at Lifesci Capital cut their FY2026 earnings per share estimates for Eupraxia Pharmaceuticals in a research note issued on Monday, March 16th. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($0.88) per share for the year, down from their prior estimate of ($0.75). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share.

Several other brokerages also recently issued reports on EPRX. Zacks Research downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Cantor Fitzgerald raised their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. HC Wainwright decreased their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock opened at $7.60 on Thursday. The company has a market capitalization of $273.30 million, a price-to-earnings ratio of -7.38 and a beta of 1.27. Eupraxia Pharmaceuticals has a one year low of $2.68 and a one year high of $9.32. The company’s 50-day moving average is $8.28 and its 200 day moving average is $6.88.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after acquiring an additional 59,683 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the last quarter. Quadrature Capital Ltd bought a new position in Eupraxia Pharmaceuticals during the second quarter valued at approximately $61,000. Bank of America Corp DE lifted its position in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the period. Finally, TCI Wealth Advisors Inc. purchased a new stake in Eupraxia Pharmaceuticals in the third quarter worth approximately $65,000.

More Eupraxia Pharmaceuticals News

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and an $11.00 price target on EPRX — this provides a clear bullish endorsement that can support the share price. Read More.
• Positive Sentiment: Lifesci Capital maintained a “Strong-Buy” stance on the stock, signaling continued institutional conviction despite model changes. Read More.
• Neutral Sentiment: HC Wainwright published detailed quarterly and multi‑year EPS projections (Q1–Q4 2026 and out-year forecasts through FY2030), giving investors updated guidance to model future cash needs and valuation — useful but not immediately directional. Read More.
• Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell,” which can pressure sentiment and trigger selling by model-driven funds or cautious retail investors. Read More.
• Negative Sentiment: HC Wainwright significantly cut EPS forecasts across multiple years (notably FY2026–FY2029 and FY2028), worsening near‑term profitability expectations and raising concerns about cash burn or longer timelines to commercialization. That reduction in earnings outlook is a substantive negative for valuation. Read More.
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (from -$0.75 to -$0.88) — a deterioration in near-term forecasts that may offset some of the positive signal from its “Strong-Buy” rating. Read More.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.